Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | TGM2 | P21980 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20913878 | 0.87 | ITGB3 (0.43) | LMNASMN1; SMN2HTTPREPMEN1 | |
| SCHEMBL19448421 | 0.87 | ITGB3 (0.43) | LMNASMN1; SMN2HTTPREPMEN1 | |
| SCHEMBL24692787 | 0.77 | KDM1A (0.48) | LMNASMN1; SMN2HTTPREPGAA | |
| SCHEMBL4501178 | 0.76 | KDM1A (0.48) | SMN1; SMN2HTTMEN1KMT2AKDM1A | |
| SCHEMBL14638266 | 0.75 | CTSB (0.47) | SMN1; SMN2DPP7DPP4KCNH2 | |
| SCHEMBL28009627 | 0.75 | CTSS (0.42) | SMN1; SMN2GAADPP7DPP4KCNH2 | |
| SCHEMBL3977628 | 0.75 | LMNA (0.48) | LMNASMN1; SMN2HTTGAAMEN1 | |
| SCHEMBL20744116 | 0.74 | JAK2 (0.47) | SMN1; SMN2MEN1KMT2ADPP7DPP4 | |
| SCHEMBL31737329 | 0.74 | LMNA (0.52) | LMNASMN1; SMN2HTTGAAMEN1 | |
| SCHEMBL20697084 | 0.73 | LMNA (0.61) | LMNASMN1; SMN2HTTGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3440069-B1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| EP-3440075-B1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-05-23 | — | — | US | disclosed |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
| EP-3440069-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| EP-3440075-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017174621-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017174620-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | BRD4, BRD3, BRDT | LMNA 1919/4885SMN1; SMN2 3654/4885HTT 3207/4885 |
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | BRD4, BRD3, BRD2 | LMNA 1875/4885SMN1; SMN2 3232/4885HTT 2360/4885 |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | LMNA 1919/4885SMN1; SMN2 3654/4885HTT 3207/4885 |
| US-20190151279-A1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | LMNA 1875/4885SMN1; SMN2 3232/4885HTT 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.